Skip to main content
Back to King's College London homepage
Hassan Jafari

Dr Hassan Jafari PhD

Statistician

Biography

Dr Hassan Jafari joined Department of Biostatistics and Health Informatics, King's College London as a statistician, working primarily on the set up, conduct and analysis of clinical trials supported by the King’s Clinical Trials Unit. In 2017 he completed a Master of Sciences in Quantitative Analysis in Social Sciences (University of Leuven, Belgium) and he is now finishing a PhD in Health Psychology (University of Leuven, Belgium). Prior to this, he obtained a PhD in physiotherapy (Iran University of Medical Sciences). Hassan is interested in the application of Multilevel Models and Psychometrics in health and medical data. 

Research interests

  • Psychophysiology of pain and disability
  • Psychophysiology of cardiovascular system
  • Psychometrics

    Research

    People walking
    Mental Health & Neuroscience Clinical Trial Statistics Group

    The Mental Health & Neuroscience Clinical Trial Statistics Group leads on the design, conduct and reporting of clinical trials in mental health.

    avatar logo
    AVATAR2

    AVATAR therapy offers a new approach to working with distressing voices (auditory hallucinations), using digital technology to allow ‘face-to-face’ dialogue between the voice-hearer and a computerised representation of their voice (the avatar). We are now taking this forward in the AVATAR2 trial.

      Research

      People walking
      Mental Health & Neuroscience Clinical Trial Statistics Group

      The Mental Health & Neuroscience Clinical Trial Statistics Group leads on the design, conduct and reporting of clinical trials in mental health.

      avatar logo
      AVATAR2

      AVATAR therapy offers a new approach to working with distressing voices (auditory hallucinations), using digital technology to allow ‘face-to-face’ dialogue between the voice-hearer and a computerised representation of their voice (the avatar). We are now taking this forward in the AVATAR2 trial.